{"id":111527,"date":"2025-06-17T14:09:54","date_gmt":"2025-06-17T05:09:54","guid":{"rendered":"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/"},"modified":"2025-08-22T10:08:52","modified_gmt":"2025-08-22T01:08:52","slug":"cln3-juvenile-batten-disease-overview","status":"publish","type":"post","link":"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en","title":{"rendered":"Juvenile Neuronal Ceroid Lipofuscinosis Type 3 (CLN3 Disease) \u3010CLN3\u3011"},"content":{"rendered":"\n<div style=\"height:18px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div style=\"border: 4px solid #e9e4f5; background-color: #fcfbff; border-radius: 12px; padding: 1.5rem; margin: 1.5rem 0 2.5rem; font-family: 'Helvetica Neue', sans-serif; line-height: 1.6; box-shadow: 0 2px 8px rgba(0, 0, 0, 0.03);\">\n  <div id=\"ez-toc-container\" class=\"ez-toc-v2_0_84 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">\u76ee\u6b21<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en\/#Gentle_Summary\" >Gentle Summary<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en\/#Implicated_Genomic_Region\" >Implicated Genomic Region<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en\/#Disorder\" >Disorder<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en\/#Overview\" >Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en\/#Epidemiology\" >Epidemiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en\/#Etiology\" >Etiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en\/#Symptoms\" >Symptoms<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en\/#Testing_Diagnosis\" >Testing &amp; Diagnosis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en\/#Treatment_Management\" >Treatment &amp; Management<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en\/#Prognosis\" >Prognosis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en\/#Helpful_Terms\" >Helpful Terms<\/a><\/li><\/ul><\/nav><\/div>\n<h2 style=\"margin-top: 0; margin-bottom: 0.75rem; font-size: 1.25rem; color: #7e6cae; text-align: left; border: none; border-bottom: none; padding-bottom: 0; display: block;\"><span class=\"ez-toc-section\" id=\"Gentle_Summary\"><\/span>Gentle Summary<span class=\"ez-toc-section-end\"><\/span><\/h2>\n  <p style=\"margin: 0; font-size: 1rem; color: #444;\">\n    CLN3 disease (juvenile Batten disease) is a rare inherited neurological condition that often begins in childhood with a gradual loss of vision.<br>\n    As the disease progresses, it slowly affects learning abilities, language, and motor skills, and seizures or emotional symptoms may also appear.<br>\n    This article clearly and thoroughly explains the mechanisms of the disease, the diagnostic process, available treatments, and daily care and support options.<br>\n    We hope this information helps reduce anxiety for families and makes it easier to communicate effectively with healthcare professionals.<br>\n    It is intended as a helpful resource for children diagnosed with CLN3 disease, their families, and those providing support.\n  <\/p>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Implicated_Genomic_Region\"><\/span><strong><strong><strong>Implicated Genomic Region<\/strong><\/strong><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div style=\"height:18px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center\"><strong>CLN3<\/strong><\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large\"><img decoding=\"async\" width=\"1024\" height=\"26\" src=\"\/nipt\/wp-content\/uploads\/2025\/06\/CLN3-hgtIdeo_genome_asia_d5568_e3ac0-1024x26.png\" alt=\"CLN3\" class=\"wp-image-101560\"\/><\/figure><\/div>\n\n\n<div style=\"height:18px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>CLN3-related disorders are caused by abnormalities in the <strong>CLN3 gene<\/strong>. The CLN3 gene is located on the short arm of <strong>chromosome 16 (16p12.1)<\/strong> and spans approximately 25,000 base pairs. It is a <strong>protein-coding gene<\/strong>, meaning it contains the instructions for producing a protein.<br>This protein, called <strong>battenin<\/strong>, is located in the membranes of <strong>lysosomes<\/strong> (small organelles inside cells responsible for breaking down and recycling waste materials). Battenin is thought to play an important role in processes such as <strong>autophagy<\/strong>, the recycling and cleaning system of the cell.The most common genetic mutation found in CLN3 disease is the <strong>1.02-kilobase (kb) deletion mutation<\/strong>, where exons 7 and 8 (segments of the gene) are missing from the CLN3 gene. This deletion is identified in about <strong>85% of patients worldwide<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Disorder\"><\/span><strong><strong><strong>Disorder<\/strong><\/strong><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The official name of this condition is <strong>Neuronal Ceroid Lipofuscinosis type 3 (CLN3)<\/strong>. It is more commonly referred to as <strong>Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)<\/strong> or <strong>Juvenile Batten Disease<\/strong>.CLN3 disease is one of a group of inherited neurodegenerative disorders collectively known as <strong>Neuronal Ceroid Lipofuscinoses (NCLs)<\/strong>. These conditions are characterized by the <strong>abnormal accumulation of autofluorescent fatty pigments (lipofuscin and ceroid)<\/strong> in nerve and eye cells. This accumulation gradually impairs the function of neurons and other affected cells.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Overview\"><\/span><strong><strong><strong>Overview<\/strong><\/strong><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>CLN3 disease is a <strong>progressive neurodegenerative disorder<\/strong> that begins in childhood and is caused by mutations in the CLN3 gene. Children who have been developing typically often show a <strong>sudden decline in vision<\/strong> between the ages of <strong>4 and 7 years<\/strong>.<\/p>\n\n\n\n<p>As the disease progresses, additional symptoms gradually appear, such as <strong>learning difficulties, language regression, seizures (epilepsy), and motor decline<\/strong>.<\/p>\n\n\n\n<p>A characteristic finding of CLN3 disease is the <strong>accumulation of fatty pigments with a distinctive \u201cfingerprint profile\u201d pattern<\/strong> in lysosomes. This accumulation is particularly evident in the <strong>brain and the retina<\/strong> (the light-sensitive tissue at the back of the eye).At present, there is <strong>no curative therapy<\/strong> available. However, supportive care, symptom management, and participation in clinical trials provide opportunities to improve quality of life and slow symptom progression.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Epidemiology\"><\/span><strong><strong>Epidemiology<\/strong><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>CLN3 disease is <strong>rare<\/strong>, with an estimated incidence of <strong>1 to 4 cases per 100,000 live births<\/strong>. It is more commonly reported in populations of <strong>Northern European (Scandinavian) descent<\/strong>, though cases have been documented worldwide.<br>Among the NCL disorders, <strong>juvenile-onset CLN3 disease is the most common subtype<\/strong>.When both parents are carriers of a pathogenic CLN3 mutation, there is a <strong>25% (1 in 4)<\/strong> chance that their child will be affected.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Etiology\"><\/span><strong><strong><strong>Etiology<\/strong><\/strong><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>CLN3 disease follows an <strong>autosomal recessive inheritance pattern<\/strong>. This means that a child must inherit a defective copy of the CLN3 gene from <strong>both parents<\/strong> in order to develop the disease.Under normal circumstances, the CLN3 gene plays a crucial role in <strong>lysosomal function<\/strong>, the system that handles waste disposal and recycling in cells. When the gene is defective, these processes do not work correctly, leading to the <strong>accumulation of waste substances such as ceroid and lipofuscin<\/strong> in nerve and other cells. Over time, this buildup causes <strong>cell death<\/strong>, progressively impairing neurological functions such as <strong>vision, movement, cognition, and behavior<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Symptoms\"><\/span><strong><strong>Symptoms<\/strong><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/early-nipt-august-only\/\">Early<\/a> Symptoms (ages 4\u20138):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vision loss<\/strong>: Often the first symptom. Rapid degeneration of the retina leads to significant visual decline. Many children become <strong>legally blind<\/strong> by around age 10.<br><\/li>\n\n\n\n<li><strong>Learning difficulties and language regression<\/strong>: Increasing difficulty with learning new skills, and loss of previously acquired language abilities.<br><\/li>\n\n\n\n<li><strong>Sleep disturbances<\/strong>: Difficulty sleeping through the night or waking frequently.<br><\/li>\n<\/ul>\n\n\n\n<p><strong>Mid to Late Stage (ages 10\u201320):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Seizures (Epilepsy)<\/strong><strong><br><\/strong><\/li>\n\n\n\n<li><strong>Motor dysfunction<\/strong>: Stiffness or spasticity in the limbs, slowed movements, and impaired balance.<br><\/li>\n\n\n\n<li><strong>Speech disorders<\/strong>: Slurred speech (<strong>dysarthria<\/strong>) and <strong>neurogenic stuttering<\/strong> are common.<br><\/li>\n\n\n\n<li><strong>Psychiatric symptoms<\/strong>: Some individuals may experience <strong>hallucinations or delusional episodes<\/strong>.<br><\/li>\n\n\n\n<li><strong>Cardiac arrhythmias<\/strong>: Irregular heart rhythms may appear in adulthood.<br><\/li>\n\n\n\n<li><strong>Feeding and swallowing difficulties<\/strong>: Dysphagia can become severe, requiring nutritional support such as tube feeding.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Testing_Diagnosis\"><\/span><strong><strong><strong>Testing &amp; Diagnosis<\/strong><\/strong><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong><a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/early-nipt-august-only\/\">Early<\/a> detection is critical.<\/strong> Diagnostic evaluation typically includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Peripheral blood smear<\/strong><strong><br><\/strong> Identification of <strong>vacuolated lymphocytes<\/strong>, a hallmark finding of CLN3 disease.<br><\/li>\n\n\n\n<li><strong>Electroretinography (ERG)<\/strong><strong><br><\/strong> Tests retinal response to light. CLN3 disease often shows a <strong>\u201cnegative ERG\u201d<\/strong> pattern, with a smaller b-wave than a-wave.<br><\/li>\n\n\n\n<li><strong>Optical Coherence Tomography (OCT)<\/strong><strong><br><\/strong> High-resolution imaging of retinal layers showing <strong>structural thinning or disorganization<\/strong> in CLN3 disease.<br><\/li>\n\n\n\n<li><strong>Genetic testing<\/strong><strong><br><\/strong> Detection of the <strong>1.02 kb deletion<\/strong> in CLN3 confirms the diagnosis. Full sequencing may be performed to identify other variants.<br><\/li>\n\n\n\n<li><strong>Electron microscopy<\/strong><strong><br><\/strong> Tissue samples (from sweat glands or conjunctiva) may reveal lysosomal inclusions with a <strong>fingerprint profile<\/strong> pattern.<br><\/li>\n\n\n\n<li><strong>EEG and MRI<\/strong><strong><br><\/strong> Evaluate epileptic activity and progressive brain atrophy.<br><\/li>\n\n\n\n<li><strong>Behavioral and functional assessments<br><\/strong> Tools such as the <strong>Vineland-3<\/strong> or the <strong>Unified Batten Disease Rating Scale (UBDRS)<\/strong> measure daily living skills and cognitive changes over time.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Treatment_Management\"><\/span><strong><strong>Treatment &amp; Management<\/strong><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Currently, there is <strong>no approved curative therapy<\/strong> for CLN3 disease. Treatment focuses on <strong>symptom management<\/strong> and <strong>quality of life<\/strong> through multidisciplinary care.<\/p>\n\n\n\n<p><strong>Supportive and Symptomatic Management<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Seizure control<\/strong>: Medications such as <strong>levetiracetam<\/strong> or <strong>valproic acid<\/strong><strong><br><\/strong><\/li>\n\n\n\n<li><strong>Motor symptom management<\/strong>: Muscle relaxants like <strong>baclofen<\/strong>, <strong>botulinum toxin<\/strong> injections, and physical therapy<br><\/li>\n\n\n\n<li><strong>Speech and communication support<\/strong>: Speech therapy and <strong>augmentative and alternative communication (AAC)<\/strong> devices<br><\/li>\n\n\n\n<li><strong>Nutritional support<\/strong>: Feeding tubes when swallowing difficulties arise<br><\/li>\n\n\n\n<li><strong>Behavioral and mental health support<\/strong>: Counseling and medications to manage anxiety, obsessive behaviors, or depression<br><\/li>\n\n\n\n<li><strong>Multidisciplinary care<\/strong>: Coordination between <strong>pediatric neurologists, ophthalmologists, rehabilitation specialists, genetic counselors, psychologists, and palliative care teams<\/strong> is essential.<\/li>\n<\/ul>\n\n\n\n<p><strong>Future Therapies Under Investigation<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gene therapy<\/strong>: Using viral vectors to deliver a functional CLN3 gene (in clinical trials)<br><\/li>\n\n\n\n<li><strong>Molecular therapies and antisense oligonucleotides<\/strong>: Currently in preclinical or early research stages.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prognosis\"><\/span><strong><strong>Prognosis<\/strong><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>CLN3 disease is a <strong>slowly progressive neurodegenerative disorder<\/strong>. While disease course varies among individuals, the general trajectory includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Complete blindness by around age 10<\/strong><strong><br><\/strong><\/li>\n\n\n\n<li><strong>Severe motor and speech impairment by late teens or early 20s<\/strong>, often requiring wheelchair support<br><\/li>\n\n\n\n<li><strong>Life expectancy<\/strong> typically ranges from the <strong>late teens to the late 20s<\/strong>, though survival into the early 30s has been reported.<br><\/li>\n<\/ul>\n\n\n\n<p>A <strong>milder variant<\/strong> with only visual impairment and minimal or delayed neurological symptoms has also been described, allowing for longer survival into adulthood.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Helpful_Terms\"><\/span><strong>Helpful Terms<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gene<\/strong>: The \u201cblueprint\u201d of the body, inherited half from each parent, influencing health and disease susceptibility.<br><\/li>\n\n\n\n<li><strong>CLN3 gene<\/strong>: The blueprint for a protein that supports lysosomal function. When defective, waste accumulates in cells, particularly in the brain and eyes.<br><\/li>\n\n\n\n<li><strong>Autosomal recessive inheritance<\/strong>: A genetic pattern in which a child must inherit a defective copy from both parents to manifest the disease.<br><\/li>\n\n\n\n<li><strong>Lysosome<\/strong>: The cell\u2019s \u201crecycling center,\u201d breaking down and processing waste materials. Dysfunction leads to cell stress and damage.<br><\/li>\n\n\n\n<li><strong>Ceroid lipofuscin<\/strong>: Yellowish pigment deposits formed from accumulated cellular debris, toxic when they build up in neurons and retinal cells.<br><\/li>\n\n\n\n<li><strong>NCL (Neuronal Ceroid Lipofuscinosis)<\/strong>: A group of disorders marked by lysosomal accumulation of ceroid lipofuscin, causing progressive neurological impairment.<br><\/li>\n\n\n\n<li><strong>Juvenile<\/strong>: Indicates onset during childhood, typically between ages 4 and 8.<br><\/li>\n\n\n\n<li><strong>Batten disease<\/strong>: A general term sometimes used to describe NCL disorders, including CLN3 disease.<br><\/li>\n\n\n\n<li><strong>1.02 kb deletion<\/strong>: A common pathogenic variant in CLN3 where part of the gene is missing, highly associated with disease onset.<br><\/li>\n\n\n\n<li><strong>Vision loss<\/strong>: Often the earliest clinical sign, progressing to complete blindness.<br><\/li>\n\n\n\n<li><strong>Seizure<\/strong>: Abnormal bursts of electrical activity in the brain, leading to involuntary movements or loss of consciousness.<br><\/li>\n\n\n\n<li><strong>Developmental regression<\/strong>: Loss of previously acquired skills in language, cognition, or motor abilities.<br><\/li>\n\n\n\n<li><strong>Vacuolated lymphocyte<\/strong>: A blood cell finding typical of CLN3, serving as an early diagnostic clue.<br><\/li>\n\n\n\n<li><strong>Retina<\/strong>: The light-sensitive tissue at the back of the eye, essential for vision.<br><\/li>\n\n\n\n<li><strong>ERG (Electroretinography)<\/strong>: Eye test measuring retinal response to light, often abnormal in CLN3.<br><\/li>\n\n\n\n<li><strong>OCT (Optical Coherence Tomography)<\/strong>: Eye imaging technique to assess thinning and structural changes in the retina.<br><\/li>\n\n\n\n<li><strong>Genetic testing<\/strong>: DNA testing to identify pathogenic variants for confirmation of diagnosis.<br><\/li>\n\n\n\n<li><strong>Dysarthria<\/strong>: Speech impairment caused by poor motor control of the tongue, lips, or mouth.<br><\/li>\n\n\n\n<li><strong>AAC (Augmentative and Alternative Communication)<\/strong>: Tools and methods, such as eye-tracking devices or communication boards, to aid communication when speech becomes difficult.<br><\/li>\n\n\n\n<li><strong>Multidisciplinary care<\/strong>: Team-based care involving various specialists to optimize outcomes.<br><\/li>\n\n\n\n<li><strong>Palliative care<\/strong>: Supportive care aimed at comfort and quality of life, recommended early in progressive diseases like CLN3.<br><\/li>\n\n\n\n<li><strong>Genetic counseling<\/strong>: Professional guidance to help families understand inheritance patterns, testing results, and implications for family planning.<\/li>\n<\/ul>\n\n\n\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"Article\",\n  \"mainEntityOfPage\": {\n    \"@type\": \"WebPage\",\n    \"@id\": \"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\"\n  },\n  \"headline\": \"What is CLN3 Disease (Juvenile Batten Disease)? Symptoms, Diagnosis, and Support | Hiro Clinic\",\n  \"description\": \"CLN3 disease (juvenile Batten disease) is a progressive neurodegenerative disorder that begins with vision loss. This article explains the causes, diagnosis, treatments, and family support methods in a clear and accessible way.\",\n  \"datePublished\": \"2025-06-17\",\n  \"inLanguage\": \"en\",\n  \"author\": {\n    \"@type\": \"Person\",\n    \"name\": \"HUMEDIT Content Team\"\n  },\n  \"publisher\": {\n    \"@type\": \"Organization\",\n    \"name\": \"Hiro Clinic\",\n    \"url\": \"https:\/\/www.hiro-clinic.or.jp\",\n    \"logo\": {\n      \"@type\": \"ImageObject\",\n      \"url\": \"https:\/\/www.hiro-clinic.or.jp\/logo.png\"\n    }\n  },\n  \"about\": {\n    \"@type\": \"MedicalCondition\",\n    \"name\": \"CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis)\",\n    \"alternateName\": \"Juvenile Batten Disease\",\n    \"description\": \"A progressive neurodegenerative disease caused by pathogenic variants in the CLN3 gene. It is characterized by vision loss, cognitive and motor regression, seizures, and other neurological symptoms.\",\n    \"cause\": {\n      \"@type\": \"MedicalCause\",\n      \"name\": \"Loss-of-function mutations in the CLN3 gene\"\n    },\n    \"possibleTreatment\": [\n      {\n        \"@type\": \"MedicalTherapy\",\n        \"name\": \"Symptomatic therapy (management of seizures, motor symptoms, speech therapy, etc.)\"\n      },\n      {\n        \"@type\": \"MedicalTherapy\",\n        \"name\": \"Clinical trials (gene therapy, targeted molecular therapy, etc.)\"\n      }\n    ],\n    \"signOrSymptom\": [\n      {\n        \"@type\": \"MedicalSignOrSymptom\",\n        \"name\": \"Vision impairment (childhood onset)\"\n      },\n      {\n        \"@type\": \"MedicalSignOrSymptom\",\n        \"name\": \"Regression of language and cognitive abilities\"\n      },\n      {\n        \"@type\": \"MedicalSignOrSymptom\",\n        \"name\": \"Seizures\"\n      },\n      {\n        \"@type\": \"MedicalSignOrSymptom\",\n        \"name\": \"Motor dysfunction and gait difficulties\"\n      }\n    ]\n  }\n}\n<\/script>\n","protected":false},"excerpt":{"rendered":"Gentle Summary CLN3 &#8230;\n <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/cln3-juvenile-batten-disease-overview\/?lang=en\">\u7d9a\u304d\u3092\u8aad\u3080<\/a>","protected":false},"author":79,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[97],"tags":[],"class_list":["post-111527","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts\/111527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/users\/79"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/comments?post=111527"}],"version-history":[{"count":9,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts\/111527\/revisions"}],"predecessor-version":[{"id":111583,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts\/111527\/revisions\/111583"}],"wp:attachment":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/media?parent=111527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/categories?post=111527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/tags?post=111527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}